🟢 Amneal Pharmaceuticals is trading 8.9% up today after raising 2026 guidance and beating Q2 estimates

Amneal Pharmaceuticals is trading at $20.15 (8.9% up) after reporting strong second-quarter results and raising its 2026 financial outlook.

• The company posted 10% revenue growth, beat adjusted EPS expectations, and raised its full-year revenue and EBITDA guidance.
• Management emphasized a strategic pivot toward higher-margin specialty and biosimilar products, which investors are rewarding in after-hours trading.